Miglustat 化学特性,用途語,生産方法
説明
This orally active glucosylceramide glucosyltransferase
inhibitor, was launched for the treatment of type I Gaucher’s
disease. Miglustat (XVI) has been developed and
launched by Oxford GlycoSciences (OGS; now Celltech) and
Actelion.
使用
Treatment of glycolipid storage diseases.
Miglustat 上流と下流の製品情報
原材料
準備製品